Targeting the chromosome partitioning protein ParA in tuberculosis drug discovery

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2347-2358

  Nisa, Shahista ^a   Blokpoel, Marian C J ^b   Robertson, Brian D ^b   Tyndall, Joel D A ^c   Lun, Shichun ^d   Bishai, William R ^d   O'Toole, Ronan ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Cell division; Essential gene; Mycobacterium; Tuberculosis

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIINFECTIVE AGENT; CHROMOSOME PROTEIN; CLOROTEPINE; PHENOXYBENZAMINE; PROTEIN INHIBITOR; PROTEIN PARA; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ANTISENSE VECTOR; ARTICLE; BACTERIAL GROWTH; ENZYME ACTIVITY; IN VITRO STUDY; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATASES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CHROMOSOME SEGREGATION; DIBENZOTHIEPINS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; HUMANS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PHENOXYBENZAMINE; RNA, ANTISENSE;

EID: 77957873650     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq311     Document Type: Article

References (68)

1. Berman HM, Westbrook J, Feng Z et al. The Protein Data Bank. Nucleic Acids Res 2000; 28: 235-42.
2. Hershkovitz I, Donoghue HD, Minnikin DE et al. Detection and molecular characterization of 9,000-year-old Mycobacterium tuberculosis from a Neolithic settlement in the Eastern Mediterranean. PLoS ONE 2008; 3: e3426.
3. WHO. World Health Organization Report 2009. Global Tuberculosis Control: Epidemiology; Strategy; Financing. http://www.who.int/tb/publications/global_report/2009/pdf/full_report.pdf (10 August 2010, date last accessed).
4. IUATLD. International Union Against Tuberculosis and Lung Disease, Anti-Tuberculosis Drug Resistance in the World, Report No. 4. 2008.
5. WHO. World Health Organization and the Stop TB Partnership. Building on and Enhancing DOTS to Meet the TB-Related Millennium Development Goals. http://www.who.int/tb/publications/2006/stop_tb_strategy.pdf (10 August 2010, date last accessed).
6. Espinal MA, Kim SJ, Suarez PG et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000; 283: 2537-45.
7. CDC. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301-5.
8. Matteelli A, Migliori GB, Cirillo D et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007; 5: 857-71.
9. WHO. World Health Organization Press Release, 5 September 2006. WHO Concern Over Extensive Drug Resistant TB Strains That Are Virtually Untreatable. http://www.who.int/mediacentre/news/notes/2006/np23/en/index.html (10 August 2010, date last accessed).
10. WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. http://www.whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf (10 August 2010, date last accessed).
11. WHO. World Health Organization and the Stop TB Partnership. Global Plan to Stop TB. http://www.who.int/tb/features_archive/global_plan_to_stop_tb/en/index.html (10 August 2010, date last accessed).
12. Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci 2004; 9: 975-94.
13. Chopra P, Meena LS, Singh Y. New drug targets for Mycobacterium tuberculosis. Indian J Med Res 2003; 117:1-9.
14. Hasan S, Daugelat S, Rao PS et al. Prioritizing genomic drug targets in pathogens: application to Mycobacterium tuberculosis. PLoS Comput Biol 2006; 2: e61.
15. Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol 2006; 6: 459-67.
16. Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
17. Camus JC, Pryor MJ, Medigue C et al. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148: 2967-73.
18. Errington J, Daniel RA, Scheffers DJ. Cytokinesis in bacteria. Microbiol Mol Biol Rev 2003; 67: 52-65, table of contents.
19. Leonard TA, Moller-Jensen J, Lowe J. Towards understanding the molecular basis of bacterial DNA segregation. Philos Trans R Soc Lond B Biol Sci 2005; 360: 523-35.
20. Ryan KR, Shapiro L. Temporal and spatial regulation in prokaryotic cell cycle progression and development. Annu Rev Biochem 2003; 72: 367-94.
21. Margalit DN, Romberg L, Mets RB et al. Targeting cell division: small-molecule inhibitors of FtsZ GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc Natl Acad Sci USA 2004; 101: 11821-6.
22. Projan SJ. New (and not so new) antibacterial targets-from where and when will the novel drugs come? Curr Opin Pharmacol 2002; 2: 513-22.
23. White EL, Southworth K, Ross L et al. A novel inhibitor of Mycobacterium tuberculosis pantothenate synthetase. J Biomol Screen 2007; 12: 100-5.
24. Bhat J, Rane R, Solapure SM et al. High-throughput screening of RNA polymerase inhibitors using a fluorescent UTP analog. J Biomol Screen 2006; 11: 968-76.
25. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003; 48: 77-84.
26. Smeulders MJ, Keer J, Speight RA et al. Adaptation of Mycobacterium smegmatis to stationary phase. J Bacteriol 1999; 181: 270-83.
27. O'Toole R, Smeulders MJ, Blokpoel MC et al. A two-component regulator of universal stress protein expression and adaptation to oxygen starvation in Mycobacterium smegmatis. J Bacteriol 2003; 185: 1543-54.
28. Belisle JT, Mahaffey SB, Hill PJ. Isolation of Mycobacterium species genomic DNA. In: Parish T, Brown AC, eds. Mycobacteria Protocols. 2nd Edn. New York, NY: Humana Press. 2008; 1-12.
29. Blokpoel MC, Murphy HN, O'Toole R et al. Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res 2005; 33: e22.
30. Bourn WR, Jansen Y, Stutz H et al. Creation and characterisation of a high-copy-number version of the pAL5000 mycobacterial replicon. Tuberculosis 2007; 87: 481-8.
31. Miller CH, Nisa S, Dempsey S et al. Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. Antimicrob Agents Chemother 2009; 53: 5279-83.
32. Studier FW. Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif 2005; 41: 207-34.
33. Eswar N, Webb B, Marti-Renom MA et al. Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics 2006; Supplement 15: 5.6.1-30.
34. Cole JC, Murray CW, Nissink JW et al. Comparing protein-ligand docking programs is difficult. Proteins 2005; 60: 325-32.
35. McQuade TJ, Shallop AD, Sheoran A et al. A nonradioactive high-throughput assay for screening and characterization of adenylation domains for nonribosomal peptide combinatorial biosynthesis. Anal Biochem 2009; 386: 244-50.
36. Ji Y, Yin D, Fox B et al. Validation of antibacterial mechanism of action using regulated antisense RNA expression in Staphylococcus aureus. FEMS Microbiol Lett 2004; 231: 177-84.
37. Ebersbach G, Gerdes K. Plasmid segregation mechanisms. Annu Rev Genet 2005; 39: 453-79.
38. Leonard TA, Butler PJ, Lowe J. Bacterial chromosome segregation: structure and DNA binding of the Soj dimmer-a conserved biological switch. EMBO J 2005; 24: 270-82.
39. Charles PG, Grayson ML. The dearth of new antibiotic development: why we should be worried and what we can do about it. Med J Aust 2004; 181: 549-53.
40. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 2005; 36: 697-705.
41. Koonin EV. How many genes can make a cell: the minimal-gene-set concept. Annu Rev Genomics Hum Genet 2000; 1: 99-116.
42. Schumacher MA. Structural biology of plasmid segregation proteins. Curr Opin Struct Biol 2007; 17: 103-9.
43. Lee PS, Grossman AD. The chromosome partitioning proteins Soj (ParA) and Spo0J (ParB) contribute to accurate chromosome partitioning, separation of replicated sister origins, and regulation of replication initiation in Bacillus subtilis. Mol Microbiol 2006; 60: 853-69.
44. Hayes F, Barillà D. Assembling the bacterial segrosome. Trends Biochem Sci 2006; 31: 247-50.
45. Bouet J-Y, Funnell BE. P1 ParA interacts with the P1 partition complex at parS and an ATP-ADP switch controls ParA activities. EMBO J 1999; 18: 1415-24.
46. Surtees JA, Funnell BE. Plasmid and chromosome traffic control: how ParA and ParB drive partition. Curr Top Dev Biol 2003; 56: 145-80.
47. Parish T, Stoker NG. Development and use of a conditional antisense mutagenesis system in mycobacteria. FEMS Microbiol Lett 1997; 154: 151-7.
48. Ehrt S, Guo XV, Hickey CM et al. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 2005; 33: e21.
49. Wu S, Howard ST, Lakey DL et al. The principal sigma factor sigA mediates enhanced growth of Mycobacterium tuberculosis in vivo. Mol Microbiol 2004; 51: 1551-62.
50. Forsyth RA, Haselbeck RJ, Ohlsen KL et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 2002; 43: 1387-400.
51. Ji Y, Zhang B, Van SF et al. Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 2001; 293: 2266-9.
52. Wang B, Kuramitsu HK. Inducible antisense RNA expression in the characterization of gene functions in Streptococcus mutans. Infect Immun 2005; 73: 3568-76.
53. Jakimowicz D, Brzostek A, Rumijowska-Galewicz A et al. Characterization of the mycobacterial chromosome segregation protein ParB and identification of its target in Mycobacterium smegmatis. Microbiology 2007; 153: 4050-60.
54. Ondeyka JG, Zink DL, Young K et al. Discovery of bacterial fatty acid synthase inhibitors from a Phoma species as antimicrobial agents using a new antisense-based strategy. J Nat Prod 2006; 69: 377-80.
55. Wang J, Kodali S, Lee SH et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci USA 2007; 104: 7612-6.
56. Wang J, Soisson SM, Young K et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441: 358-61.
57. Young K, Jayasuriya H, Ondeyka JG et al. Discovery of FabH/FabF inhibitors from natural products. Antimicrob Agents Chemother 2006; 50: 519-26.
58. Betts JC, Lukey PT, Robb LC et al. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43: 717-31.
59. Tehan BG, Lloyd EJ, Wong MG. Molecular field analysis of clozapine analogs in the development of a pharmacophore model of antipsychotic drug action. J Mol Graph Model 2001; 19: 417-26, 468.
60. Leysen JE, Janssen PM, Schotte A et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology (Berl) 1993; 112: S40-54.
61. Metysová JMJ, Dlabac A, Kazdová E, Valchár M. Pharmacological properties of a potent neuroleptic drug octoclothepin. Acta Biol Med Ger 1980; 39: 723-40.
62. Tomás-Vert F, Pérez-Giménez F, Salabert-Salvador MT et al. Artificial neural network applied to the discrimination of antibacterial activity by topological methods. J Mol Struct (Theochem) 2000; 504: 249-59.
63. Cronin MTD, Aptula AO, Dearden JC et al. Structure-based classification of antibacterial activity. J Chem Inf Comput Sci 2002; 42: 869-78.
64. Guzzetta NA. Phenoxybenzamine in the treatment of hypoplastic left heart syndrome: a core review. Anesth Analg 2007; 105: 312-5.
65. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978; 50: 551-4.
66. Barnes CD, Eltherington LG. Drug Dosages in Laboratory Animals-A Handbook. Berkeley, USA: University of California Press, 1973.
67. Robson HG, Cluff LE. Experimental pneumococcal and staphylococcal sepsis: effects of hydrocortisone and phenoxybenzamine upon mortality rates. J Clin Invest 1966; 45: 1421-32.
68. Dong X, Stothard P, Forsythe IJ et al. PlasMapper: a web server for drawing and auto-annotating plasmid maps. Nucl Acids Res 2004; 32: W660-4.